drugset / Trial / NCT05435027
Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The primary objective is to assess the safety and tolerability of samRNA vaccines GRT-R912, GRT-R914, and GRT-R918 when administered as prime and/or boost in healthy adult participants naïve to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV-2 convalescent, previously vaccinated, or non-vaccinated participants, and people living with HIV (PLWH) or HIV-negative.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2024-03-06
- Completion
- 2024-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRT-R912 | Small activating RNA (saRNA) | — | Intramuscular |
| Subject | GRT-R914 | Small activating RNA (saRNA) | 3 ug | Intramuscular |
| Subject | GRT-R914 | Small activating RNA (saRNA) | 10 ug | Intramuscular |
| Subject | GRT-R914 | Small activating RNA (saRNA) | 30 ug | Intramuscular |
| Subject | GRT-R918 | Small activating RNA (saRNA) | — | Intramuscular |